Esophageal Cancer Diagnosis
Esophageal Cancer Diagnosis
Four questions are answered in order: is there a tumour, how deep has it gone, has it reached the nodes, and has it spread. Endoscopy answers the first, endoscopic ultrasound the second, and CT with PET-CT the rest.
Endoscopy: where the diagnosis is made
Upper gastrointestinal endoscopy is the diagnostic standard, and it does three things at once. It visualises the whole length of the oesophagus, it measures how far from the incisors a lesion begins and ends — which is how the level of the tumour is recorded — and it takes biopsies. The procedure takes about ten minutes with sedation, and for a patient with a stricture it may include dilation, though dilation before a diagnosis is made is generally avoided because it risks perforating an unresected tumour.
- Describing the lesion — the distance from the incisors, the length, the degree of narrowing, and whether the surface is ulcerated, nodular or flat.
- Biopsy — several samples from the edge of the lesion rather than its centre, where necrosis is more likely, so that the pathologist receives viable tumour.
- Assessing the stomach and duodenum — because a second primary tumour in the upper aerodigestive tract is not rare in patients with squamous carcinoma linked to tobacco and alcohol.
- Checking for a fistula — in advanced disease, a communication between the oesophagus and the airway changes the plan immediately.
The report is more useful when it is detailed. "Tumour at 30 cm" tells a surgeon little; "a 5 cm ulcerated stricture from 28 to 33 cm from the incisors, not passable, biopsies taken" tells the radiotherapy planner and the operating surgeon what they need before they see the patient.
Chromoendoscopy: finding lesions that look normal
Early squamous cell carcinoma and high-grade dysplasia often look like nothing — a small area of redness or roughness, or a patch that is impossible to distinguish from inflammation. Lugol's iodine chromoendoscopy solves this. Iodine stains normal squamous epithelium dark brown because of its glycogen content; dysplastic and malignant epithelium contains less glycogen and stays unstained, appearing as a clearly demarcated pale area against the brown background.
- What it finds — high-grade dysplasia and early squamous carcinoma that would otherwise be missed, including multifocal lesions and satellite patches away from the main tumour.
- Why it matters — a lesion confined to the mucosa can be removed endoscopically, so finding it before it reaches the submucosa changes the treatment from an operation to a scope procedure.
- Where it is routine — in high-incidence regions and in screening programmes, where the yield justifies its use in every examination.
- What it does not do — it is not useful for adenocarcinoma, which is assessed by the Barrett's segment and by Seattle-protocol biopsies instead.
This is also the reason the diagnosis of an early oesophageal cancer is so dependent on where the endoscopy is performed. An examination that visualises and biopsies the obvious lesion will diagnose the cancer; an examination that also uses chromoendoscopy will find the second lesion alongside it, which is what makes endoscopic treatment complete.
Endoscopic ultrasound, CT and PET-CT
The three tests describe different things, and the word to keep in mind is that they are not substitutes for one another:
- Endoscopic ultrasound — a probe in the oesophagus itself, imaging the wall in layers. It is the test that measures depth — mucosa, submucosa, muscle, adventitia — and it assesses the nodes immediately beside the oesophagus. It is what separates a lesion that can be removed endoscopically from one that needs an operation.
- Contrast-enhanced CT of chest and abdomen — shows how far the tumour has grown in relation to the airway, aorta and pleura, and detects enlarged nodes and liver or lung deposits. It does not measure depth.
- PET-CT — detects distant spread that CT may miss, including in bone and in distant lymph nodes, and is used where metastatic disease would change the plan or where a CT finding is equivocal.
- Barium swallow — largely historical, but still used where a stricture cannot be passed endoscopically, to define the length and shape of the narrowing.
- Bronchoscopy — for tumours of the upper and middle oesophagus, to check whether the airway is involved, which affects both resectability and radiotherapy planning.
The practical consequence is that a plan built on CT alone is incomplete. The depth of the tumour, which endoscopic ultrasound provides, decides between endoscopic removal, surgery and chemoradiotherapy — three treatments with very different consequences for the patient.
Staging: what the tests are looking for
Staging oesophageal cancer means answering four questions, each by a different part of the work-up:
- How deep is the tumour? Endoscopic ultrasound, with high-frequency probes for the earliest lesions. This is the question that decides between endoscopic and surgical treatment.
- How far has it grown outwards? CT and bronchoscopy. Tumour touching the pleura, pericardium or diaphragm remains removable; tumour invading the aorta, trachea or a vertebral body does not.
- Are the nodes involved? Endoscopic ultrasound and CT together, and PET-CT for nodes outside the chest. Because the lymphatic drainage runs lengthwise, nodes in the neck and upper abdomen matter as much as those beside the tumour.
- Is there distant spread? PET-CT primarily, with CT. The liver, lungs, bones and distant nodes are the usual sites, and their presence changes the aim of treatment from cure to control.
The output of staging is not only a stage number but a decision: whether the lesion can be removed endoscopically, whether an operation is possible after chemoradiotherapy, or whether chemoradiotherapy is the definitive treatment. That decision is best made with the endoscopy findings, the endoscopic ultrasound and the imaging all in front of the same team.
Reading the pathology report
The pathology report from the biopsy carries more decision-making weight in this cancer than in most, and four items in it are worth finding:
- Histological type — squamous cell carcinoma or adenocarcinoma. This determines the chemotherapy regimen, the radiotherapy field and the way the operation is planned.
- Grade — how differentiated the tumour is. Poorly differentiated tumours behave more aggressively and are staged differently within the AJCC system.
- HER2 status — relevant in adenocarcinoma, and the finding that makes trastuzumab an option in advanced disease.
- PD-L1 combined positive score, and mismatch repair status — both determine whether an immune checkpoint inhibitor is likely to help, and both are easiest to obtain from the original diagnostic biopsy.
Two practical points. If the biopsy report describes only "carcinoma" without a type, or if the sample was too small for molecular testing, asking for repeat sampling before treatment begins is reasonable — the type and the markers are not details that can be decided later. And if a lesion has been removed endoscopically elsewhere, the specimen itself should be re-reviewed, because the depth of invasion in the resected specimen is what confirms whether the endoscopic treatment was sufficient.
Arranging the work-up from abroad
Most of the oesophageal work-up can be reviewed remotely, and the items that matter are specific:
- The endoscopy report and images — the distance from the incisors, the length, the appearance, and whether chromoendoscopy was used.
- The histology and molecular results — type, grade, HER2, PD-L1 and mismatch repair status. If the original request did not include them, they can usually be added to existing tissue.
- The endoscopic ultrasound report — the T and N assessment. Without it, the choice between endoscopic treatment and surgery cannot be made.
- The CT on disc, in DICOM format rather than a PDF, plus any PET-CT and barium swallow.
- Nutritional information — current weight, weight lost, and whether swallowing has become difficult enough to affect intake.
Where a test has not been done, it can be arranged quickly on arrival, but it should be a decision made with the existing material already reviewed rather than a routine first step. Where a lesion is early, the assessment should include a view on whether it can be treated endoscopically — because that option is time-sensitive and is not available once the tumour has become deeper.